Huperzine A
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Huperzine A
- Molecular weight
- 242.32
- Structure (SMILES)
- C/C=C1\[C@H]2C=C(C)C[C@]1(N)c1ccc(=O)[nH]c1C2
- (-)-huperzine a
- (-)-selagine
- (5R,9R,11E)-5-AMINO-11-ETHYLIDENE-5,6,9,10-TETRAHYDRO-7-METHYL-5,9-METHANOCYCLOOCTA(B)PYRIDIN-2(1H)-ONE
- 5r 9r 11e 5 amino 11 ethylidene 5 6 9 10 tetrahydro 7 methyl 5 9 methanocycloocta b pyridin 2 1h one
- huperzine a
- huperzine A
- Huperzine a
- Huperzine A
- HUPERZINE A [MI]
- HUPERZINE A [VANDF]
- Huperzine a [WHO-DD]
- huperzine a 0 4 mg
- huperzine a 0 8 mg
- Huperzine A 0.4 mg
- Huperzine A 0.8 mg
- huperzine a for injection
- Huperzine A for Injection
- huperzine a injection
- Huperzine A injection
- Huperzine A Injection
- huperzine a mi
- huperzine a oral solution
- Huperzine A Oral Solution
- huperzine a vandf
- huperzine a who dd
And 4 more, listed on the interactive page.
- CAS registry numbers
- 102518-79-6
- ChEMBL ID
- CHEMBL395280
- InChIKey
- ZRJBHWIHUMBLCN-YQEJDHNASA-N
- PubChem compound IDs
- 854026
- RxNorm IDs (RxCUI)
- 2267703
- FDA ingredient codes (UNII)
- 0111871I23
- Patents
- 0
- Designations
- 3
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- huperzine A
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- acetylcholinesterase (Yt blood group)
- Gene symbol
- ACHE
- Protein identifier
- P22303
- Median affinity
- 7.77
- Affinity units
- pKd
- Mechanism
- Acetylcholinesterase inhibitor
- Action type
- Inhibitor
- Target
- Acetylcholinesterase
- Protein identifier
- P22303
Open Targets mechanisms
- Mechanism
- Acetylcholinesterase inhibitor
- Action type
- Inhibitor
- Target
- Acetylcholinesterase
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002491
- Subject identifier
- D019966
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004456
- Subject identifier
- D019970
- Condition
- Alzheimer Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Brain Injuries
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0043510
- Subject identifier
- D001930
- Condition identifier
- HP_0100543
- Condition identifier
- MONDO_0004456
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 4
- NCT00083590
- NCT01282619
- NCT01030692
- NCT01676311
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 58.88
- Calculated partition coefficient (ALogP)
- 2
- Calculated partition coefficient (XLogP)
- 0
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 18
- Molecular formula
- C15H18N2O
- Monoisotopic mass
- 242.141913202
- Natural product
- Yes
- Recorded assays
- 1,156
- Active assays
- 72
- Confirmatory
- Other
- Cholinesterase Inhibitors
- Neuroprotective Agents
Related records
Trials (13)
- A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery
- Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage
- Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
- Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A
- Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
- Effects of Huperzine A in Treatment of Moderate to Severe TBI
- Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
- Huperzine A in Alzheimer's Disease
- Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia
- Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants
- Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
- The Study of Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
- The Study of Pharmacokinetics and Pharmacodynamics of Huperzine A Injection in Healthy Chinese Subjects
In development for (4)
- Alzheimer disease Phase 2
- Brain injury Phase 2
- Cocaine abuse Phase 1
- Substance abuse Phase 1
Targets (1)
- ACHE Acetylcholinesterase inhibitor